Literature DB >> 12538318

Partial splenectomy in cystic fibrosis patients with hypersplenism.

G H Thalhammer1, E Eber, S Uranüs, J Pfeifer, M S Zach.   

Abstract

We report three cystic fibrosis (CF) patients with hypersplenism who underwent partial splenectomy. The postoperative course was uneventful in two patients; one patient developed a complication necessitating resection of the rest of the spleen. Haematological parameters improved and oesophageal varices regressed in all patients. On follow up, one patient showed a normal spleen, the other a normally functioning accessory spleen; the third patient again developed splenomegaly with hypersplenism. Partial splenectomy is a promising therapeutic option for CF patients with hypersplenism.

Entities:  

Mesh:

Year:  2003        PMID: 12538318      PMCID: PMC1719430          DOI: 10.1136/adc.88.2.143

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  41 in total

1.  Prevalence of liver disease in cystic fibrosis.

Authors:  R Scott-Jupp; M Lama; M S Tanner
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

2.  Partial splenic embolization. An effective alternative to splenectomy for hypersplenism.

Authors:  R Shah; G H Mahour; E G Ford; P Stanley
Journal:  Am Surg       Date:  1990-12       Impact factor: 0.688

3.  Cystic fibrosis and portal hypertension interest of partial splenectomy.

Authors:  D Louis; J P Chazalette
Journal:  Eur J Pediatr Surg       Date:  1993-02       Impact factor: 2.191

Review 4.  Hepatobiliary pathology in patients with cystic fibrosis.

Authors:  M Sinaasappel
Journal:  Acta Paediatr Scand Suppl       Date:  1989

Review 5.  Partial splenectomy for symptomatic splenic hamartoma.

Authors:  R J Havlik; R J Touloukian; R I Markowitz; P Buckley
Journal:  J Pediatr Surg       Date:  1990-12       Impact factor: 2.545

Review 6.  Complications and limitations of injection sclerotherapy in portal hypertension.

Authors:  N D Heaton; E R Howard
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

7.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

8.  Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

Authors:  J Feigelson; C Anagnostopoulos; M Poquet; Y Pecau; A Munck; J Navarro
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

9.  Partial splenectomy in children with Gaucher's disease.

Authors:  J A Bar-Maor; J Govrin-Yehudain
Journal:  Pediatrics       Date:  1985-09       Impact factor: 7.124

10.  Evaluation of endoscopic sclerotherapy of esophageal varices in children.

Authors:  T J Donovan; M Ward; R W Shepherd
Journal:  J Pediatr Gastroenterol Nutr       Date:  1986 Sep-Oct       Impact factor: 2.839

View more
  5 in total

1.  A novel spleen-preserving laparoscopic technique using radiofrequency ablation in a porcine model.

Authors:  E Pikoulis; E Felekouras; I Papaconstantinou; M Kontos; E Prassas; I Griniatsos; C Bacoyiannis; P Pappa; A Papalois; C Tsigris; A Giannopoulos; E Papalambros; J Bramis; E Bastounis
Journal:  Surg Endosc       Date:  2005-07-21       Impact factor: 4.584

2.  Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series.

Authors:  B Linnane; M R Oliver; P J Robinson
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

3.  Cystic fibrosis-related liver disease: a single-center experience.

Authors:  Paula Catarino Costa; Celeste Canha Barreto; Luisa Pereira; Maria Luisa Lobo; Maria Adília Costa; Ana Isabel Gouveia Lopes
Journal:  Pediatr Rep       Date:  2011-10-17

4.  Analysis of multiple gene co-expression networks to discover interactions favoring CFTR biogenesis and ΔF508-CFTR rescue.

Authors:  Matthew D Strub; Long Gao; Kai Tan; Paul B McCray
Journal:  BMC Med Genomics       Date:  2021-10-30       Impact factor: 3.622

Review 5.  Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.

Authors:  Matthew D Strub; Paul B McCray
Journal:  Genes (Basel)       Date:  2020-05-13       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.